Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Drug shows promise against Sudan strain of Ebola in mice

29.08.2014

Antibody therapy could fight second-most deadly strain of virus

Researchers from Albert Einstein College of Medicine of Yeshiva University and other institutions have developed a potential antibody therapy for Sudan ebolavirus (SUDV), one of the two most lethal strains of Ebola. A different strain, the Zaire ebolavirus (EBOV), is now devastating West Africa. First identified in 1976, SUDV has caused numerous Ebola outbreaks (most recently in 2012) that have killed more than 400 people in total. The findings were reported in ACS Chemical Biology.

Between 30 and 90 percent of people infected with Ebola die after experiencing symptoms of the disease that include fever, muscle aches, vomiting and bleeding. In the current EBOV outbreak, at least 1,500 people have died as of the end of August.

Two U.S. aid workers infected in that outbreak received an experimental treatment called ZMapp, a combination of three different monoclonal antibodies that bind to the protein of the virus. The newly described SUDV treatment also uses monoclonal antibodies, in this case synthetic antibodies designed to target a key molecule on the surface of SUDV called the envelope glycoprotein. (A glycoprotein molecule consists of carbohydrates plus a protein).

"While our antibodies show promise for treatment of SUDV infection, they wouldn't work against the EBOV outbreak now underway in West Africa," said Jonathan Lai, Ph.D., associate professor of biochemistry at Einstein and co-corresponding author of the ACS Chemical Biology paper. "That's because antibodies that kill off one strain, or species, of Ebola haven't proven effective against other strains."

In developing their SUDV therapy, the researchers started with specific antibodies made by mice. These antibodies protect the animals against SUDV infection by binding to the envelope glycoprotein on the surface of the virus. But if used in humans, mouse antibodies could provoke an immune response that would destroy them. Needing a "humanized" version of their mouse antibody, the researchers realized that its molecular structure closely resembled the structure of a commonly used human antibody.

The researchers used that human antibody as a scaffold onto which they placed the Ebola-specific portion of the mouse antibody. They then made variants of the resulting molecule by subtly changing its structure in different ways using a process called "synthetic antibody engineering". Two of these variants proved able to fend off SUDV in specially bred mice. "These two monoclonal antibodies represent potential candidates for treating SUDV infection," said Dr. Lai. He noted that more research is needed before the antibody therapy can be tested on humans.

###

The study, titled "Synthetic Antibodies with a Human Framework that Protect Mice from Lethal Sudan Ebolavirus Challenge," was published online in ACS Chemical Biology on August 20, 2014. In addition to Dr. Lai, other co-corresponding authors were John M. Dye, Ph.D., of the United States Army Medical Research Institute of Infectious Diseases, and Sachdev S. Sidhu, Ph.D., of the University of Toronto. Other Einstein authors were Jayne Koellhoffer, B.S., Julia Frei, B.S., Nina Liu, and Kartik Chandran, Ph.D. Additional authors are Gang Chen, Ph.D., Hua Long, Wei Ye, B.Sc., Kaajal Nagar, and Guohua Pan, Ph.D., all of University of Toronto, and Samantha Zak of the U.S. Army.

The study was funded by grants from the National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health (AI090249, AI088027 and AI09762), the Canadian Institutes for Health Research (MOP-93725) and the Defense Threat Reduction Agency.

About Albert Einstein College of Medicine of Yeshiva University

Albert Einstein College of Medicine of Yeshiva University is one of the nation’s premier centers for research, medical education and clinical investigation. During the 2013-2014 academic year, Einstein is home to 743 M.D. students, 275 Ph.D. students, 103 students in the combined M.D./Ph.D. program, and 313 postdoctoral research fellows. The College of Medicine has more than 2,000 full-time faculty members located on the main campus and at its clinical affiliates. In 2013, Einstein received more than $150 million in awards from the National Institutes of Health (NIH). This includes the funding of major research centers at Einstein in aging, intellectual development disorders, diabetes, cancer, clinical and translational research, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Its partnership with Montefiore Medical Center, the University Hospital and academic medical center for Einstein, advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. Through its extensive affiliation network involving Montefiore, Jacobi Medical Center –- Einstein’s founding hospital, and three other hospital systems in the Bronx, Brooklyn and on Long Island, Einstein runs one of the largest residency and fellowship training programs in the medical and dental professions in the United States. For more information, please visit www.einstein.yu.edu, read our blog, follow us on Twitter, like us on Facebook, and view us on YouTube.

Kim Newman | Eurek Alert!
Further information:
http://www.einstein.yu.edu

Further reports about: ACS Biology Drug Ebola Einstein Health Medical Medicine Sudan outbreak strain structure variants

More articles from Life Sciences:

nachricht Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH

nachricht Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>